drugset / Trial / NCT00861692
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral antithrombotic therapy
Timeline
- Start
- 2009-04
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Argatroban | Small molecule | 0.77 ug/kg | Other |